NCT06687070 - APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions

Platinum-resistant Recurrent Ovarian CancerAdvanced Solid Tumor

Interventions

DRUG

APG -2449

Orally once a day(QD), every 28 days as a cycle.

DRUG

PLD

Injected on the first day of each cycle, every 28 days as a cycle.

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou